Esperion Therapeutics (ESPR) said Thursday it has signed a licensing deal with Neopharm Israel for the exclusive rights to commercialize cholesterol medications Nexletol and Nexlizet in Israel.
Under the terms of the agreement, Esperion will grant Neopharm exclusive commercialization rights to the drugs in Israel, Gaza, and the West Bank.
In return, Esperion will receive upfront and near-term milestone payments, and will be eligible to receive tiered royalties on sales of the drugs in Israel.
Price: 2.62, Change: -0.07, Percent Change: -2.79
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments